TY - JOUR
T1 - Clinical magnetic hyperthermia requires integrated magnetic particle imaging
AU - Healy, Sean
AU - Bakuzis, Andris F.
AU - Goodwill, Patrick W.
AU - Attaluri, Anilchandra
AU - Bulte, Jeff W.M.
AU - Ivkov, Robert
N1 - Funding Information:
R.I., J.W.M.B., P.W.G., and A.A. received funding from the National Cancer Institute (1R01 CA257557). R.I. received partial funding from the National Cancer Institute (5R01 CA194574‐02 and 5R01CA247290), and from the Jayne Koskinas and Ted Giovanis Foundation for Health and Policy (JKTGF). J.W.M.B. received funding for MPI from the NIH (S10 OD026740, UH 3EB028904), the Maryland Stem Cell Fund (MSCRFD‐5416), and Philips Healthcare Inc. P.W.G received funding from the National Institute for Biomedical Imaging and Bioengineering (R44 EB029877). The School of Science, Engineering, and Technology, The Pennsylvania State University–Harrisburg, provided additional financial support for A.A. A.F.B. received partial funding from the Brazilian agencies CNPq (310230/2017‐9) and FAPEG (201710267000511). The content is solely the responsibility of the authors and does not necessarily represent the official view of the National Institutes of Health, JKTGF, or other funding agencies and Pennsylvania State University, Johns Hopkins University, and Universidade Federal de Goiás. Funding information
Publisher Copyright:
© 2022 The Authors. WIREs Nanomedicine and Nanobiotechnology published by Wiley Periodicals LLC.
PY - 2022/5/1
Y1 - 2022/5/1
N2 - Magnetic nanomaterials that respond to clinical magnetic devices have significant potential as cancer nanotheranostics. The complexities of their physics, however, introduce challenges for these applications. Hyperthermia is a heat-based cancer therapy that improves treatment outcomes and patient survival when controlled energy delivery is combined with accurate thermometry. To date, few technologies have achieved the needed evolution for the demands of the clinic. Magnetic fluid hyperthermia (MFH) offers this potential, but to be successful it requires particle-imaging technology that provides real-time thermometry. Presently, the only technology having the potential to meet these requirements is magnetic particle imaging (MPI), for which a proof-of-principle demonstration with MFH has been achieved. Successful clinical translation and adoption of integrated MPI/MFH technology will depend on successful resolution of the technological challenges discussed. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease Diagnostic Tools > In Vivo Nanodiagnostics and Imaging.
AB - Magnetic nanomaterials that respond to clinical magnetic devices have significant potential as cancer nanotheranostics. The complexities of their physics, however, introduce challenges for these applications. Hyperthermia is a heat-based cancer therapy that improves treatment outcomes and patient survival when controlled energy delivery is combined with accurate thermometry. To date, few technologies have achieved the needed evolution for the demands of the clinic. Magnetic fluid hyperthermia (MFH) offers this potential, but to be successful it requires particle-imaging technology that provides real-time thermometry. Presently, the only technology having the potential to meet these requirements is magnetic particle imaging (MPI), for which a proof-of-principle demonstration with MFH has been achieved. Successful clinical translation and adoption of integrated MPI/MFH technology will depend on successful resolution of the technological challenges discussed. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease Diagnostic Tools > In Vivo Nanodiagnostics and Imaging.
UR - http://www.scopus.com/inward/record.url?scp=85125537512&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85125537512&partnerID=8YFLogxK
U2 - 10.1002/wnan.1779
DO - 10.1002/wnan.1779
M3 - Review article
C2 - 35238181
AN - SCOPUS:85125537512
SN - 1939-0041
VL - 14
JO - Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology
JF - Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology
IS - 3
M1 - e1779
ER -